...
首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats.
【24h】

Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats.

机译:内源性血管紧张素-(1-7)减轻了糖尿病性高血压大鼠的心脏缺血性功能障碍。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Angiotensin-(1-7) [Ang-(1-7)] is a vasodilator peptide with cardiac and vascular protective properties. We examined the influence of Ang-(1-7), both endogenous and after chronic treatment with the peptide (576mug/(kgday)), on ischemia/reperfusion (I/R)-induced cardiac dysfunction in streptozotocin-treated spontaneously hypertensive rats (diabetic SHR). In isolated perfused hearts, recovery of left ventricular function from 40min of global ischemia was improved significantly in Ang-(1-7)- or captopril-treated diabetic SHR and worsened in animals treated with A779, an Ang-(1-7) receptor (AT((1-7))) antagonist. The beneficial effect of captopril on cardiac recovery was reduced when co-administered with A779. Cardiac NF-kappaB activity appears to be higher in diabetic SHR and treatment with Ang-(1-7) or captopril decreased NF-kappaB activity in diabetic SHR, an effect partially reversed by co-administration of A779. Real-time PCR-based gene array analysis of cardiac tissue revealed that Ang-(1-7) or captopril treatment may reduce expression of several genes of inflammation involved in the NF-kappaB signalling pathway. The data provide for the first time a role for endogenous Ang-(1-7) as well as confirmation that exogenous treatment with the peptide produces cardioprotection. Whether potential anti-inflammatory and transcriptional factor changes are directly linked to the cardioprotection produced by Ang-(1-7) in diabetic SHR remains to be determined.
机译:血管紧张素-(1-7)[Ang-(1-7)]是具有心脏和血管保护特性的血管扩张肽。我们检查了内源性和经肽(576mug /(kgday)长期治疗后Ang-(1-7)对链脲佐菌素治疗的自发性高血压大鼠缺血/再灌注(I / R)引起的心脏功能障碍的影响(糖尿病性SHR)。在孤立的灌注心脏中,Ang-(1-7)-或卡托普利治疗的糖尿病SHR患者从全局缺血40分钟后的左心室功能恢复显着改善,而用Ang-(1-7)受体A779治疗的动物则恶化(AT((1-7)))拮抗剂。当与A779共同使用时,卡托普利对心脏恢复的有益作用降低。糖尿病SHR中的心脏NF-kappaB活性较高,而用Ang-(1-7)或卡托普利治疗可降低糖尿病SHR中的NF-kappaB活性,这种作用可通过与A779共同给药而部分逆转。心脏组织的基于实时PCR的基因阵列分析显示,Ang-(1-7)或卡托普利治疗可能会减少涉及NF-kappaB信号通路的几种炎症基因的表达。数据首次提供了内源性Ang-(1-7)的作用,并证实了用肽进行外源性治疗可产生心脏保护作用。潜在的抗炎和转录因子变化是否与糖尿病SHR中Ang-(1-7)产生的心脏保护作用直接相关尚待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号